{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T04:19:40Z","timestamp":1776572380548,"version":"3.51.2"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014589","name":"Chief Scientist Office","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014589","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"UK Research and Innovation Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ejca.2025.115299","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:05:12Z","timestamp":1739318712000},"page":"115299","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Somatic BRCA1\/2 mutations are associated with a similar survival advantage to their germline counterparts in tubo-ovarian high grade serous carcinoma"],"prefix":"10.1016","volume":"219","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1390-3298","authenticated-orcid":false,"given":"Robert L.","family":"Hollis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Churchman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graeme R.","family":"Grimes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5839-1751","authenticated-orcid":false,"given":"Alison M.","family":"Meynert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3019-6262","authenticated-orcid":false,"given":"Philippe","family":"Gautier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynn","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kitty","family":"Sherwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0702-3892","authenticated-orcid":false,"given":"Ailsa J.","family":"Oswald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Croy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cameron W.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trevor","family":"McGoldrick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"McPhail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Creedon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Carl","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"March","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian A.","family":"Dougherty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Roxburgh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2272-1277","authenticated-orcid":false,"given":"Ailith","family":"Ewing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9177-8165","authenticated-orcid":false,"given":"C. Simon","family":"Herrington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin A.","family":"Semple","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2377-7221","authenticated-orcid":false,"given":"Charlie","family":"Gourley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.115299_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216057","article-title":"Molecular characteristics and clinical behaviour of epithelial ovarian cancers","volume":"555","author":"Hollis","year":"2023","journal-title":"Cancer Lett"},{"issue":"10","key":"10.1016\/j.ejca.2025.115299_bib2","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nrc3144","article-title":"Rethinking ovarian cancer: recommendations for improving outcomes","volume":"11","author":"Vaughan","year":"2011","journal-title":"Nat Rev Cancer"},{"issue":"7353","key":"10.1016\/j.ejca.2025.115299_bib3","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Bell","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2025.115299_bib4","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkae049","article-title":"The survival benefit associated with complete macroscopic resection in epithelial ovarian cancer is histotype-specific","author":"Porter","year":"2024","journal-title":"JNCI Cancer Spectr"},{"issue":"11","key":"10.1016\/j.ejca.2025.115299_bib5","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/nrc4019","article-title":"Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer","volume":"15","author":"Bowtell","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"34","key":"10.1016\/j.ejca.2025.115299_bib6","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1200\/JCO.2008.16.1703","article-title":"\"BRCAness\" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations","volume":"26","author":"Tan","year":"2008","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"issue":"14","key":"10.1016\/j.ejca.2025.115299_bib7","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jama.2011.1456","article-title":"Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer","volume":"306","author":"Yang","year":"2011","journal-title":"Jama"},{"issue":"8","key":"10.1016\/j.ejca.2025.115299_bib8","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.ejca.2025.115299_bib9","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"issue":"10106","key":"10.1016\/j.ejca.2025.115299_bib10","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet (Lond, Engl)"},{"issue":"3","key":"10.1016\/j.ejca.2025.115299_bib11","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas","volume":"20","author":"Pennington","year":"2014","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"issue":"16","key":"10.1016\/j.ejca.2025.115299_bib12","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1158\/1078-0432.CCR-22-0368","article-title":"Multiomic characterization of high-grade serous ovarian carcinoma enables high-resolution patient stratification","volume":"28","author":"Hollis","year":"2022","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"issue":"22","key":"10.1016\/j.ejca.2025.115299_bib13","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1200\/JCO.2009.27.2997","article-title":"Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer","volume":"28","author":"Hennessy","year":"2010","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"issue":"44","key":"10.1016\/j.ejca.2025.115299_bib14","doi-asserted-by":"crossref","first-page":"18032","DOI":"10.1073\/pnas.1115052108","article-title":"Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing","volume":"108","author":"Walsh","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"10.1016\/j.ejca.2025.115299_bib15","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/CCO.0000000000000660","article-title":"Role of poly (ADP-Ribose) polymerase inhibitors beyond BReast CAncer gene-mutated ovarian tumours: definition of homologous recombination deficiency?","volume":"32","author":"Gourley","year":"2020","journal-title":"Curr Opin Oncol"},{"issue":"7553","key":"10.1016\/j.ejca.2025.115299_bib16","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature14410","article-title":"Whole-genome characterization of chemoresistant ovarian cancer","volume":"521","author":"Patch","year":"2015","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.ejca.2025.115299_bib17","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/ng.3849","article-title":"Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes","volume":"49","author":"Wang","year":"2017","journal-title":"Nat Genet"},{"key":"10.1016\/j.ejca.2025.115299_bib18","article-title":"Divergent trajectories to structural diversity impact patient survival in high grade serous ovarian cancer","volume":"2024","author":"Ewing","year":"2024","journal-title":"bioRxiv"},{"issue":"11","key":"10.1016\/j.ejca.2025.115299_bib19","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1158\/1078-0432.CCR-20-4068","article-title":"Structural variants at the BRCA1\/2 loci are a common source of homologous repair deficiency in high-grade serous ovarian carcinoma","volume":"27","author":"Ewing","year":"2021","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"issue":"2","key":"10.1016\/j.ejca.2025.115299_bib20","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ygyno.2011.12.415","article-title":"Hereditary ovarian cancer: beyond the usual suspects","volume":"124","author":"Pennington","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"Database","key":"10.1016\/j.ejca.2025.115299_bib21","doi-asserted-by":"crossref","first-page":"D980","DOI":"10.1093\/nar\/gkt1113","article-title":"ClinVar: public archive of relationships among sequence variation and human phenotype","volume":"42","author":"Landrum","year":"2014","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"10.1016\/j.ejca.2025.115299_bib22","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/humu.20269","article-title":"The UMD TP53 database and website: update and revisions","volume":"27","author":"Hamroun","year":"2006","journal-title":"Hum Mutat"},{"issue":"4","key":"10.1016\/j.ejca.2025.115299_bib23","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nm.4292","article-title":"HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures","volume":"23","author":"Davies","year":"2017","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.ejca.2025.115299_bib24","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/jama.2012.20","article-title":"Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer","volume":"307","author":"Bolton","year":"2012","journal-title":"Jama"},{"key":"10.1016\/j.ejca.2025.115299_bib25","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.2147\/OTT.S102569","article-title":"Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer","volume":"10","author":"Hollis","year":"2017","journal-title":"OncoTargets Ther"},{"issue":"1","key":"10.1016\/j.ejca.2025.115299_bib26","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.2007.11.6905","article-title":"Effect of BRCA1\/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer","volume":"26","author":"Chetrit","year":"2008","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"issue":"17","key":"10.1016\/j.ejca.2025.115299_bib27","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1001\/jama.283.17.2260","article-title":"Clinicopathologic features of BRCA-linked and sporadic ovarian cancer","volume":"283","author":"Boyd","year":"2000","journal-title":"Jama"},{"issue":"3","key":"10.1016\/j.ejca.2025.115299_bib28","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1158\/1078-0432.CCR-14-2497","article-title":"Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer","volume":"21","author":"Candido-dos-Reis","year":"2015","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"issue":"11","key":"10.1016\/j.ejca.2025.115299_bib29","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/s41416-018-0274-8","article-title":"Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes","volume":"119","author":"Hodgson","year":"2018","journal-title":"Br J Cancer"},{"issue":"16","key":"10.1016\/j.ejca.2025.115299_bib30","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1002\/cncr.32079","article-title":"High EMSY expression defines a BRCA-like subgroup of high-grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum","volume":"125","author":"Hollis","year":"2019","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.ejca.2025.115299_bib31","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1016\/j.ejca.2014.05.001","article-title":"BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD)","volume":"50","author":"Ruscito","year":"2014","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2025.115299_bib32","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ygyno.2005.10.034","article-title":"BRCA1 promoter methylation predicts adverse ovarian cancer prognosis","volume":"101","author":"Chiang","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejca.2025.115299_bib33","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ygyno.2023.03.019","article-title":"Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial","volume":"172","author":"Pignata","year":"2023","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2025.115299_bib34","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1470-2045(22)00122-X","article-title":"Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial","volume":"23","author":"Kristeleit","year":"2022","journal-title":"Lancet Oncol"},{"issue":"27","key":"10.1016\/j.ejca.2025.115299_bib35","doi-asserted-by":"crossref","first-page":"43653","DOI":"10.18632\/oncotarget.17613","article-title":"Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting","volume":"8","author":"Dougherty","year":"2017","journal-title":"Oncotarget"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925000802?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925000802?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T09:06:30Z","timestamp":1741597590000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925000802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":35,"alternative-id":["S0959804925000802"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115299","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Somatic BRCA1\/2 mutations are associated with a similar survival advantage to their germline counterparts in tubo-ovarian high grade serous carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115299","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"115299"}}